Greenwich Wealth Management LLC Reduces Holdings in Eli Lilly and Company (NYSE:LLY)

Greenwich Wealth Management LLC lowered its position in Eli Lilly and Company (NYSE:LLY) by 2.8% in the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 2,408 shares of the company’s stock after selling 70 shares during the quarter. Greenwich Wealth Management LLC’s holdings in Eli Lilly and Company were worth $2,181,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in LLY. AMJ Financial Wealth Management bought a new stake in shares of Eli Lilly and Company in the fourth quarter valued at approximately $201,000. Aveo Capital Partners LLC boosted its holdings in Eli Lilly and Company by 8.2% in the 4th quarter. Aveo Capital Partners LLC now owns 2,020 shares of the company’s stock worth $1,178,000 after buying an additional 153 shares during the period. Gryphon Financial Partners LLC grew its stake in Eli Lilly and Company by 19.4% in the 4th quarter. Gryphon Financial Partners LLC now owns 2,324 shares of the company’s stock valued at $1,355,000 after buying an additional 377 shares in the last quarter. Main Street Financial Solutions LLC raised its holdings in Eli Lilly and Company by 2.5% during the 4th quarter. Main Street Financial Solutions LLC now owns 876 shares of the company’s stock valued at $511,000 after acquiring an additional 21 shares during the period. Finally, Motco raised its holdings in Eli Lilly and Company by 270.8% during the 4th quarter. Motco now owns 9,219 shares of the company’s stock valued at $5,374,000 after acquiring an additional 6,733 shares during the period. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Insiders Place Their Bets

In other news, major shareholder Lilly Endowment Inc sold 9,671 shares of the stock in a transaction that occurred on Thursday, June 20th. The stock was sold at an average price of $902.67, for a total transaction of $8,729,721.57. Following the completion of the sale, the insider now owns 97,574,139 shares of the company’s stock, valued at $88,077,248,051.13. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders have sold 451,900 shares of company stock valued at $418,732,178 in the last ninety days. Company insiders own 0.13% of the company’s stock.

Eli Lilly and Company Price Performance

Shares of Eli Lilly and Company stock opened at $923.71 on Monday. The company has a debt-to-equity ratio of 1.74, a quick ratio of 0.87 and a current ratio of 1.11. Eli Lilly and Company has a 52-week low of $516.57 and a 52-week high of $972.53. The company has a fifty day moving average of $897.12 and a 200-day moving average of $833.89. The stock has a market capitalization of $877.92 billion, a price-to-earnings ratio of 136.04, a price-to-earnings-growth ratio of 2.79 and a beta of 0.42.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Thursday, August 8th. The company reported $3.92 earnings per share for the quarter, topping the consensus estimate of $2.64 by $1.28. The business had revenue of $11.30 billion during the quarter, compared to the consensus estimate of $9.83 billion. Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. Equities research analysts expect that Eli Lilly and Company will post 16.49 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Tuesday, September 10th. Investors of record on Thursday, August 15th were given a dividend of $1.30 per share. The ex-dividend date of this dividend was Thursday, August 15th. This represents a $5.20 annualized dividend and a yield of 0.56%. Eli Lilly and Company’s payout ratio is 76.58%.

Analyst Ratings Changes

Several brokerages have commented on LLY. BMO Capital Markets raised their target price on Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the stock an “outperform” rating in a research note on Friday, August 9th. Berenberg Bank upped their price target on shares of Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the stock a “buy” rating in a report on Wednesday, August 14th. Wells Fargo & Company lifted their price objective on Eli Lilly and Company from $875.00 to $1,000.00 and gave the company an “overweight” rating in a research note on Friday, August 9th. Deutsche Bank Aktiengesellschaft upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating and upped their target price for the stock from $725.00 to $1,025.00 in a research note on Monday, August 12th. Finally, Bank of America lifted their price target on Eli Lilly and Company from $1,000.00 to $1,125.00 and gave the company a “buy” rating in a research report on Friday, August 9th. Three research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. Based on data from MarketBeat, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and a consensus target price of $977.35.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.